User 142431

Total Rating:
0 / 0

1 Comment

    • Mon Jan 21st 10:37 AM | Rating: 0 0
      Commented on:
      Elan, Biogen Idec Won't Gain Much from Tysabri Approval
      Perhaps with more experience you will learn to look a little deeper into your subject matter, rather than parroting questionable claims from others who failed to do their research.

      Tysabri's run rate is already higher than suggested in your article. The incidence of PML in Tysabri monotherapy is exactly 0. Assuming your figure of 500,000 with Crohns is correct, this represents a potential market of $14.5 billion, not $800 million.

      Let's hope your readers decide to dig a little deeper. You certainly did not.
      View article »
Contribute an Article Become a Seeking Alpha Contributor